Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag281 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Aleksandra Konieczna und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited. Materials and methods We conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: <65 vs ≥65 years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety.
Results
Among 303 patients, 76 (25.1%) were aged ≥65 years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status ≥1. In unadjusted analyses, patients aged ≥65 years had longer median OS (12.8 vs 10.9 months; HR, 0.70; 95% CI, 0.49-0.99; P = 0.045) and PFS (5.4 vs 4.1 months; HR, 0.73; 95% CI, 0.54-0.97; P = 0.031). ORR, DCR, treatment modifications, and grade ≥3 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS.
Conclusion
In this selected real-world cohort, patients aged ≥65 years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland.
- Department of Oncology, Breast Unit Clinical Oncology Day Care Department, Wroclaw Medical University, Lower Silesian Comprehensive Cancer Center, Wroclaw 53-413, Poland.
- Department of Clinical Oncology, Holy Cross Cancer Center, Kielce 25-734, Poland.
- Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice 44-102, Poland.
- Department of Oncology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague 100 34, Czech Republic.
- Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, and Faculty of Medicine, Masaryk University, Brno 656 53, Czech Republic.
ORCID-Profile: Aleksandra Konieczna, Anna Polakiewicz-Gilowska, Jan Šustr, Aleksandra Łacko, Michał Jarząb
Zitieren
APA
Konieczna, A., Pieniążek, M., Żubrowska, J., Polakiewicz-Gilowska, A., Soumarová, R., Holánek, M., Študentová, H., Młodzińska, A., Winsko-Szczęsnowicz, K., Lisik-Habib, M., Pękala, A., Krejčí, D., Šustr, J., Kolářová, I., Danielewicz, I., Szymanik-Resko, M., Ciszewski, T., Rušinová, L., Czartoryska-Arłukowicz, B., …, & Püsküllüoğlu, M. (2026). Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study. The Oncologist. https://doi.org/10.1093/oncolo/oyag281
Vancouver
Konieczna A, Pieniążek M, Żubrowska J, Polakiewicz-Gilowska A, Soumarová R, Holánek M, et al. Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study. The Oncologist. 2026. doi:10.1093/oncolo/oyag281
BibTeX
@article{Konieczna2026,
author = {Konieczna, Aleksandra and Pieniążek, Małgorzata and Żubrowska, Justyna and Polakiewicz-Gilowska, Anna and Soumarová, Renata and Holánek, Miloš and Študentová, Hana and Młodzińska, Agnieszka and Winsko-Szczęsnowicz, Karolina and Lisik-Habib, Maja and Pękala, Anika and Krejčí, Daniel and Šustr, Jan and Kolářová, Iveta and Danielewicz, Iwona and Szymanik-Resko, Magdalena and Ciszewski, Tomasz and Rušinová, Lenka and Czartoryska-Arłukowicz, Bogumiła and Łacko, Aleksandra and Jarząb, Michał and Kubeczko, Marcin and Pacholczak-Madej, Renata and Smok-Kalwat, Joanna and Nowecki, Zbigniew and Bielčiková, Zuzana and Malejčíková, Miroslava and Püsküllüoğlu, Mirosława},
title = {Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag281}
}
EUVIMED